Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 40 (1) , 159-168
Abstract
Metabolites can have pharmacological or toxicological effects, inhibit metabolic enzymes, and be used as probes of drug-drug interactions or specific cytochrome P450 (P450) phenotypes. Thus, better understanding and prediction methods are needed to characterize metabolite exposures in vivo. This study aimed to test whether in vitro data could be used to predict and rationalize in vivo metabolite exposures using two model drugs and P450 probes: dextromethorphan and omeprazole with their primary metabolites dextrorphan, 5-hydroxyomeprazole (5OH-omeprazole), and omeprazole sulfone. Relative metabolite exposures were predicted using metabolite formation and elimination clearances. For dextrorphan, the formation clearances of dextrorphan glucuronide and 3-hydroxymorphinan from dextrorphan in human liver microsomes were used to predict metabolite (dextrorphan) clearance. For 5OH-omeprazole and omeprazole sulfone, the depletion rates of the metabolites in human hepatocytes were used to predict metabolite clearance. Dextrorphan/dextromethorphan in vivo metabolite/parent area under the plasma concentration versus time curve ratio (AUCm/AUCp) was overpredicted by 2.1-fold, whereas 5OH-omeprazole/omeprazole and omeprazole sulfone/omeprazole were predicted within 0.75- and 1.1-fold, respectively. The effect of inhibition or induction of the metabolite9s formation and elimination on the AUCm/AUCp ratio was simulated. The simulations showed that unless metabolite clearance pathways are characterized, interpretation of the metabolic ratios is exceedingly difficult. This study shows that relative in vivo metabolite exposure can be predicted from in vitro data and characterization of secondary metabolism of probe metabolites is critical for interpretation of phenotypic data.Keywords
This publication has 36 references indexed in Scilit:
- Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypesXenobiotica, 2010
- Benzodiazepines in epilepsy: pharmacology and pharmacokineticsActa Neurologica Scandinavica, 2008
- Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell LinesDrug Metabolism and Disposition, 2008
- An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug InteractionDrug Metabolism and Disposition, 2008
- Effect of Cinacalcet Hydrochloride, a New Calcimimetic Agent, on the Pharmacokinetics of Dextromethorphan: In Vitro and Clinical StudiesThe Journal of Clinical Pharmacology, 2007
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007
- Evaluation of Dextromethorphan Metabolism Using Hepatocytes from CYP2D6 Poor and Extensive MetabolizersDrug Metabolism and Pharmacokinetics, 2005
- The antitussive effect of dextromethorphan in relation to CYP2D6 activityBritish Journal of Clinical Pharmacology, 1999
- Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin*Clinical Pharmacology & Therapeutics, 1997
- Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation*Clinical Pharmacology & Therapeutics, 1996